Background and Mechanistic Rationale
Chimeric antigen receptor T-cell (CAR-T) therapy—originally developed for hematologic malignancies—has emerged as a transformative investigational approach for severe, treatment-refractory autoimmune diseases. CAR-T cells are genetically engineered autologous or allogeneic T lymphocytes expressing a synthetic chimeric antigen receptor that combines an extracellular antigen-binding domain with intracellular T-cell activation domains, enabling potent, major histocompatibility complex (MHC)-unrestricted recognition and elimination of antigen-expressing target cells 24. In autoimmune disease, the primary therapeutic rationale centers on deep, sustained elimination of autoreactive B cells and plasma cells—a mechanism distinct from conventional B-cell depletion 111.
Anti-CD20 monoclonal antibodies (e.g., rituximab) deplete circulating B cells but fail to eliminate long-lived plasma cells or B cells sequestered in lymphoid sanctuaries and inflamed tissues 822. By contrast, CAR-T cells penetrate lymphoid organs and sites of inflammation through autonomous trafficking, achieving more complete and durable B-cell lineage depletion 318. Following depletion, B-cell reconstitution occurs with a predominantly naïve, non-class-switched phenotype—a process termed "immune reset"—suggesting elimination of autoreactive clones rather than mere transient suppression 29. Compelling early evidence arose from patients with concurrent autoimmune diseases and B-cell malignancies receiving CD19-directed CAR-T for cancer: profound and unexpected autoimmune disease remissions occurred in parallel with tumor eradication, lending mechanistic credibility to this dual efficacy 24.
Clinical Evidence by Disease Area
Systemic Lupus Erythematosus and Lupus Nephritis
Systemic lupus erythematosus (SLE) represents the most studied autoimmune indication. A pivotal case series of 5 refractory SLE patients (median Systemic Lupus Erythematosus Disease Activity Index [SLEDAI] 16) by Mackensen et al. demonstrated that all achieved Definition of Remission in SLE (DORIS) criteria by 3 months, with anti-double-stranded DNA (anti-dsDNA) seroconversion and sustained drug-free remission through a median follow-up of 8 months 4. A subsequent, larger case series by Müller et al. in 8 SLE patients extended these findings to a 15-month median follow-up, with 100% DORIS remission and complete discontinuation of immunosuppressive therapy in all patients 2. Across pooled real-world data encompassing 35 patients with SLE or juvenile-onset SLE treated with CD19- or B-cell maturation antigen (BCMA)/CD19-targeted CAR-T, lupus low disease activity state (LLDAS) was achieved in approximately 88% at 3 months and 86% at 6 months, with approximately 96% attaining a drug-free state by 3 months post-infusion 24. Notable cases include a refractory SLE patient who successfully conceived and delivered a healthy infant 6 months after BCMA/CD19 CAR-T therapy, and a juvenile-onset SLE patient with end-stage renal disease who regained partial renal function permitting dialysis discontinuation 24.
In lupus nephritis specifically, the allogeneic off-the-shelf candidate FT819 achieved primary renal response in 3 of 3 treated patients, with the first patient reaching drug-free DORIS remission at 12 months 12. KYV-101, a fully human autologous CD19 CAR-T, demonstrated anti-dsDNA normalization and stable renal function in all 4 treated patients, with 2 of 4 achieving urine protein-to-creatinine ratio (UPCR) below 0.5 g/g 12.
Idiopathic Inflammatory Myopathies and Systemic Sclerosis
Among 3 patients with idiopathic inflammatory myopathy (IIM) and 4 with systemic sclerosis (SSc) in the Müller et al. series, all achieved American College of Rheumatology–European League Against Rheumatism (ACR-EULAR) major clinical response and significant reductions in European Scleroderma Trials and Research Group (EUSTAR) activity index scores, respectively, with complete immunosuppressant discontinuation 2. Across a pooled cohort of 14 SSc patients, composite response rates (ACR Composite Response Index in dcSSc [CRISS] ≥0.6 or EUSTAR <2.5) were 58% at 3 months, escalating to 100% at 6 months—however, drug-free states were observed in only 12.5% at 3 months, reflecting residual fibrotic and vascular disease not addressable by immune reset alone 24.
Myasthenia Gravis
Two distinct CAR-T platforms have generated compelling data in refractory generalized myasthenia gravis (MG). A phase 1 trial of bispecific autologous anti-BCMA/CD19 CAR-T (n=18; MG-Activities of Daily Living [MG-ADL] ≥6) demonstrated mean reductions of −8.6 in MG-ADL and −15.4 in Quantitative MG (QMG) scores at Day 180, with 82% achieving minimal manifestations status, 88% discontinuing glucocorticoids entirely, and anti-acetylcholine receptor antibody seroconversion in 47% 6. Descartes-08, a BCMA-directed mRNA-based autologous CAR-T administered as six weekly outpatient infusions without lymphodepletion, demonstrated a randomized Phase 2b signal of 71% vs. 25% placebo achieving ≥5-point MG Composite (MGC) improvement at Month 3, with durable Month-12 responses and 83% maintaining clinically meaningful improvement 1227.
Multiple Sclerosis and Neurological Indications
Evidence in multiple sclerosis (MS) remains early. A first-in-human case series of KYV-101 in progressive MS demonstrated CAR-T cell presence in cerebrospinal fluid with suppression of intrathecal antibody production and absence of immune effector cell-associated neurotoxicity syndrome (ICANS), establishing feasibility 13. Among 3 MS patients treated with BCMA-directed autologous CAR-T (Fucaso/CT103A), all reportedly improved in Expanded Disability Status Scale (EDSS) and resolved oligoclonal bands, with no new MRI lesions through follow-up 12. In neuromyelitis optica spectrum disorder (NMOSD), 11 of 12 patients treated with Fucaso were relapse-free at a median of 5.5 months, with reduced AQP4-IgG titers 12. These results are hypothesis-generating rather than practice-defining.
Table 1. Key CAR-T Clinical Studies in Autoimmune Diseases (2021–2026)
| Study / Program | Year | Disease | N | CAR-T Target | Dose | Median Follow-up | Remission/Response Rate | Steroid/IS Discontinuation | CRS (Grade) | ICANS |
|---|---|---|---|---|---|---|---|---|---|---|
| Mackensen et al. 4 | 2022 | SLE | 5 | CD19 (autologous) | 1×10⁶/kg | 8 mo | 5/5 DORIS (100%) | 5/5 (100%) | Grade 1 only | None |
| Müller et al. 2 | 2024 | SLE (8), IIM (3), SSc (4) | 15 | CD19 (autologous) | 1×10⁶/kg | 15 mo | 100% across all | 15/15 (100%) | Grade 1–2 | Grade 1 (1 pt) |
| Bispecific BCMA/CD19 Phase 1 6 | 2024–25 | Refractory MG | 18 | BCMA/CD19 (autologous) | 1–5×10⁶/kg | 6 mo (Day 180) | 82% minimal manifestations | 88% GC DC; 100% IS DC | Grade 1 (39%) | None |
| Descartes-08 Phase 2b 1227 | 2024 | Refractory MG | 36 randomized | BCMA (mRNA, autologous) | 6 weekly infusions, no lymphodepletion | 12 mo | 71% vs 25% placebo (MGC ≥5 pts) | Not formally assessed | None | None |
| Yang et al. (allogeneic) 512 | 2025 | SLE | Small cohort | CD19 (allogeneic) | Pending full pub | Pending | Remission achieved | Pending | Pending | Pending |
| FT819 (Fate Therapeutics) 1225 | 2024–25 | SLE/LN | 5 SLE reported | CD19 (off-the-shelf/iPSC) | Flu-free cohorts | Up to 12 mo | 3/3 LN renal response; 1 drug-free DORIS at 12 mo | Reported | Grade 2 CRS (1) | None |
| Fucaso/CT103A 12 | 2023–25 | NMOSD (12), MS (3), MG (2) | 17 | BCMA (autologous) | Standard CAR-T | Median 5.5 mo | 11/12 NMOSD relapse-free | N/A | Grade 1 predominantly | None |
Abbreviations: GC DC, glucocorticoid discontinuation; IS DC, immunosuppressant discontinuation; IIM, idiopathic inflammatory myopathy; iPSC, induced pluripotent stem cell; LN, lupus nephritis; MG, myasthenia gravis; mo, months; NMOSD, neuromyelitis optica spectrum disorder; SSc, systemic sclerosis.
Table 2. Disease-Specific Outcomes Summary
| Disease | Total N (Reported) | Remission Criteria | Remission Rate | Median Follow-up | B-Cell Reconstitution | Drug-Free State |
|---|---|---|---|---|---|---|
| SLE / LN | ~35 24 | DORIS / LLDAS | LLDAS 88% at 3 mo; DORIS 100% in controlled series | 8–15 mo | ~110 days (naïve phenotype) 2 | ~96% at 3 mo |
| IIM | 3 2 | ACR-EULAR MCR | 100% | 15 mo | ~110 days | 100% |
| SSc | 14 24 | ACR-CRISS ≥0.6 or EUSTAR <2.5 | 58% at 3 mo; 100% at 6 mo | 3–15 mo | ~110 days | 12.5% (immune reset; fibrosis persists) |
| MG (bispecific) | 18 6 | Minimal manifestations (MG-ADL/QMG) | 82% | 6 mo | Not reported | 88% GC; 100% non-steroid IS |
| MG (Descartes-08) | 26 efficacy 12 | MGC ≥5-point improvement | 71% vs. 25% placebo | 12 mo | Not reported | Not formally assessed |
| NMOSD | 12 12 | Relapse-free | 92% (11/12) | 5.5 mo | Not reported | N/A |
| MS | 3–5 1213 | EDSS/MRI/OCB | Improvement in small series | Short-term | Not reported | N/A |
Safety and Tolerability
A systematic review of 80 patients across 24 studies found that cytokine release syndrome (CRS) occurred in 79 patients in mild-to-moderate grade, while only 4 patients developed neurotoxicity; critically, no fatal adverse events were reported 14. Across the Müller et al. series, 67% of patients experienced Grade 1 CRS, with a single Grade 2 CRS and one Grade 1 ICANS case; one patient required hospitalization for pneumonia 2. The bispecific BCMA/CD19 phase 1 MG trial reported no ICANS and no dose-limiting toxicities, with transient Grade 3 hematologic toxicities (leukopenia, neutropenia) all resolving with supportive care 6. Notably, Descartes-08—administered without lymphodepleting chemotherapy—reported no CRS or ICANS in either phase, with only mild constitutional symptoms 1227.
This tolerability advantage over oncology CAR-T is attributed to lower antigen burden, a less inflammatory cytokine milieu, and the absence of bulky tumor in autoimmune disease patients 24. However, two emerging concerns warrant attention: a 2025 editorial identified a novel toxicity syndrome distinct from classical CRS and ICANS occurring specifically in autoimmune disease recipients, necessitating disease-specific monitoring protocols 10; and B-cell aplasia lasting a mean of 112 days creates a window of infection risk and potential hypogammaglobulinemia requiring intravenous immunoglobulin (IVIG) replacement monitoring 28.
Table 3. Safety Profile Summary and Emerging Platform Landscape
| Safety / Platform Domain | Key Observations | Clinical Implication |
|---|---|---|
| CRS incidence and grade 2614 | Grade 1: 39–67%; Grade 2: ~7%; Grade ≥3: 0% (most series) | Self-limited; standard tocilizumab protocols applicable |
| ICANS 214 | Rare (0–6%); Grade 1 predominantly; Grade 3–4 uncommon | Monitoring required; dexamethasone effective |
| Cytopenias (Grade ≥3) 612 | Transient leukopenia/neutropenia in ~22%; all reversible | G-CSF support; generally manageable |
| Infection risk 210 | 7% pneumonia (hospitalization); opportunistic risk during B-cell aplasia | Prophylaxis; infection monitoring essential |
| Novel autoimmune-specific toxicity 10 | Emerging syndrome distinct from CRS/ICANS identified 2025 | Requires disease-specific monitoring protocols |
| Hypogammaglobulinemia 8 | Expected with prolonged B-cell aplasia | IVIG replacement if indicated; monitor immunoglobulin levels |
| Emerging Platforms | ||
| Allogeneic / off-the-shelf CAR-T 51225 | FT819 (iPSC-derived, RMAT designation); allogeneic CD19 in SLE/SSc | Reduces manufacturing barriers; shorter B-cell reconstitution; GvHD monitoring needed |
| BCMA/CD19 bispecific CAR-T 68 | Phase 1 data in MG; targets plasma cells + B cells | Potentially superior depth of depletion |
| CAAR-T 1517 | DSG3-CAART in pemphigus vulgaris (Phase 1/2); antigen-specific clone targeting | High specificity; clinical efficacy still maturing |
| CAR-Treg 828 | Regulatory T-cell CAR; secretes IL-10/TGF-β | Immunomodulation without cytotoxicity; preclinical/early phase |
| CAR-NK 2028 | Natural killer cell-based CAR platform | Potential off-the-shelf use; reduced GvHD risk |
| mRNA-based outpatient CAR-T (Descartes-08) 27 | No preconditioning; outpatient weekly infusions | Operational paradigm shift; no CRS/ICANS |
Regulatory Landscape and Future Directions
Regulatory agencies have granted Regenerative Medicine Advanced Therapy (RMAT) designations to multiple programs, signaling recognition of unmet need and therapeutic promise: FT819 for SLE with lupus nephritis (FDA; additionally selected for the CMC Development and Readiness Pilot [CDRP] Program in May 2026 25), KYV-101 for progressive MG (FDA 26), and Descartes-08 for MG (FDA 27). Across 30 patients treated with KYV-101 spanning 6 rheumatology and 9 neurology indications, durable immunomodulator-free responses (DIFRs, defined as ≥3 months without immunomodulators) were achieved in 21 of 30 patients 26. Allogeneic platforms address the manufacturing scalability and cost barriers inherent to autologous production, though theoretical graft rejection risks and shorter B-cell aplasia duration (~5 months less than autologous) require further characterization 24.
Future directions include expansion into rheumatoid arthritis, Sjögren's syndrome, anti-phospholipid antibody syndrome, pemphigus vulgaris, and progressive MS; in vivo CAR-T approaches to simplify logistics; biomarker-guided patient selection; retreatment and re-dosing strategies for relapse; combination paradigms pairing CAR-T immune induction with organ-targeted antifibrotic or vasoactive therapies (particularly in SSc); and standardized outcome measure frameworks across trials 82123.
Evidence Quality and Clinical Uncertainty
Current evidence derives almost exclusively from small, uncontrolled case series and early-phase trials with short follow-up (3–15 months), predominantly from single institutions in Germany, China, and the United States 1424. The largest single cohort encompasses 18 patients (bispecific MG trial 6); the only truly randomized dataset is Descartes-08 in MG 12. Heterogeneous endpoints (DORIS, LLDAS, SLEDAI-2K, UPCR, MGC, MG-ADL, EDSS, ACR-CRISS, EUSTAR), publication bias favoring positive results, cohort overlap across publications, and reliance on company press releases and conference abstracts in some reports substantially limit cross-study comparability 1224. Long-term durability beyond 24 months, relapse incidence and retreatment efficacy, secondary malignancy risk, late infection consequences of hypogammaglobulinemia, and cost-effectiveness remain entirely uncharacterized. No randomized controlled trial comparing CAR-T with standard-of-care immunosuppression has been completed in any autoimmune indication 923.
Conclusion
CAR-T cell therapy represents a scientifically compelling and clinically promising approach to refractory autoimmune disease, with early evidence of high remission rates, immunosuppressant-free states, and immune reset across SLE, IIM, SSc, MG, and selected neurological indications. The safety profile in autoimmune populations appears more favorable than in oncology, though emerging disease-specific toxicity syndromes, infection risk, and manufacturing and cost barriers must not be underestimated 101424. Multiple regulatory RMAT designations signal institutional recognition of therapeutic promise 252627. Nevertheless, the evidence base remains limited in scope and duration. CAR-T should currently be positioned as an investigational therapy for carefully selected, severely refractory patients within clinical trials or formally supervised compassionate-use programs. Adequately powered, randomized, long-term trials with standardized endpoints are the essential next step before integration into routine clinical practice 91923.